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Sir,
We read with great interest the article ‘Daily 300 mg dose of line-
zolid for multidrug-resistant and extensively drug-resistant tu-
berculosis: updated analysis of 51 patients’ by Koh et al.,1 in
which they describe retrospectively examined records of one of
the largest case series of patients treated with linezolid for
multidrug-resistant and extensively drug-resistant tuberculosis
(MDR/XDR-TB). They describe the long-term outcomes of
51 patients, whereas the previous study only described the short-
term outcomes of 17 patients.2 Their objective was to evaluate
the efficacy, tolerability and adverse events of a 300 mg daily
dose of linezolid in the treatment of MDR/XDR-TB. Based on a fa-
vourable treatment outcome of 78%, compared with 60%–
100% in the literature albeit in smaller case series, they
suggest that linezolid is effective against intractable MDR/
XDR-TB at a daily dose of 300 mg. In our opinion it is difficult
to draw this conclusion from the presented data. The lack of a
control group makes it impossible to attribute a favourable
outcome in patients to a single drug such as linezolid as it is
only a part of an expanded treatment regimen. Favourable treat-
ment outcomes could very well be caused by other drugs of the
expanded regimen the patients received.
To implicate the efficacy of their linezolid-containing
regimen, Koh et al.1 make assumptions on the MIC of linezolid
for their population and the linearity of linezolid pharmacokin-
etics. They assume their patients are infected with Mycobacter-
ium tuberculosis with an MIC of linezolid of 0.25 mg/L. Koh
et al.1 base this on a recent study that described wild-type
MIC distributions of linezolid and six other second-line drugs
for 78 consecutive susceptible clinical isolates.3 Although
most isolates had an MIC of linezolid of 0.25 mg/L, the wild-
type MIC distribution ranged from 0.125 to 0.5 mg/L and an
epidemiological cut-off (ECOFF) value of 0.5 mg/L was sug-
gested.3 The fact that we found the MIC to be 0.5 mg/L in
eight isolates, 1 mg/L in eight isolates and even .1 mg/L in
one isolate in a previous study of 23 isolates,4 may raise
some doubt about the assumption that all clinical isolates
have an MIC value of 0.25 mg/L.
Koh et al.1 assume the pharmacokinetics of linezolid to be
linear. Unfortunately, the pharmacokinetics of linezolid are
not linear in TB patients, as we demonstrated in a previous
study.5 Besides, substantial intra- and interpatient variability of
linezolid in TB patients can be observed. We found the AUC0–12
of 300 mg twice daily to be 56 mg.h/L, but with an IQR of
38.5–64.2 mg.h/L.
We agree with Koh et al.1 that for linezolid the fAUC0 – 24/MIC
ratio is often used as a predictive model for efficacy.5 Koh et al.1
refer to data of Schon et al.3 suggesting that a daily dose of
600 mg linezolid would lead to an fAUC of 56 mg.h/L, resulting
in an fAUC/MIC ratio of 100 for a wild-type MICECOFF of
0.5 mg/L and of 200 for the more common MIC of 0.25 mg/L.
In both cases, the pharmacodynamic target of fAUC/MIC .100
is met. However, during the study period, drug susceptibility
testing (DST) as well as plasma concentration monitoring [thera-
peutic drug monitoring (TDM)] were not performed for linezolid.
This is very unfortunate, since linezolid is the drug of interest in
their study. As a consequence, it is unknown if the pharmacoki-
netic/pharmacodynamic target of fAUC0 – 24/MIC .100 is met.
Therefore, in our opinion, it is not correct to assume linezolid to
be effective without DST and TDM for linezolid or without a
control group.
Finally, we also do not support the conclusion that Koh et al.1
draw from the presented data that a daily dose of 300 mg of
linezolid may be associated with fewer neuropathic side effects
than a daily dose of 600 or 1200 mg. It was necessary to
cease linezolid therapy in 14 patients (27%) due to neurotoxicity,
which is within the range of the highly variable incidence of
neurotoxicity of 4%–89% at daily doses of 600 or 1200 mg as
presented by Koh et al.1 in an overview of the literature.
Despite the daily dose of linezolid being low, the duration of ad-
ministration of linezolid is long, with a median of 278 days. This
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Sir,
We would like to thank Bolhuis et al.1 for their recent comments
regarding our paper.2 The treatment of multidrug-resistant
(MDR) and extensively drug-resistant (XDR) tuberculosis (TB) pre-
sents a major challenge. As noted by Bolhuis et al.,1 the lack of a
control group in our study was a major limitation; however, we
must point out that our patients had ‘intractable’ MDR/XDR-TB.
Of the 51 patients examined in our study, 51% had XDR-TB, and
the rate of resistance to ofloxacin was 98%.2 Aggressive
management using linezolid resulted in a favourable outcome
for more than 75% of patients who had been unsuccessfully
treated with second-line anti-TB drugs for a median of
40 months.2 These figures are comparable to those reported
by other studies that show that linezolid (600–1200 mg/day)
is effective for the treatment of MDR/XDR-TB.3,4 As linezolid
was used as part of a multidrug regimen that included higher
generation fluoroquinolones, the favourable treatment out-
comes may not be attributable to linezolid alone. However, in
our opinion, it is unethical to perform a comparative trial
(patients treated with or without linezolid) in patients with in-
tractable MDR/XDR-TB because, in such patients, current treat-
ments including linezolid may be the last chance of being
cured. Instead, we believe that a clinical trial comparing the ef-
ficacy and tolerability of different doses of linezolid should be
performed. At present, a clinical trial comparing 600 mg/day
and 300 mg/day linezolid for the treatment of XDR-TB is under
way in Korea (ClinicalTrials.gov number NCT00727844).5 –7
The absence of drug susceptibility results and pharmacoki-
netic data for linezolid was another major limitation in our
study. However, irrespective of this, the major finding in our
paper was that a substantial portion of intractable MDR/
XDR-TB patients successfully completed treatment. Our previ-
ous paper showed that the mean serum Cmin of linezolid
(300 mg/day) was 2.1+1.3 mg/L (range 0.4–4.5 mg/L), the
mean serum Cmax was 11.6+4.4 mg/L (range 1.5–15.9 mg/L)
and the MIC99 for Mycobacterium tuberculosis was 0.25 mg/L
for 30% of the isolates and 0.5 mg/L for 70%.8 Therefore, we
were unable to draw any final conclusions from our study
regarding the drug susceptibility and pharmacokinetic para-
meters of linezolid.2
Our data could not support a definitive conclusion that a
300 mg daily dose of linezolid would reduce the incidence of
neuropathy. Previous studies from Korea had reported that
neuropathy developed in 50%–80% of patients treated with
600 mg/day linezolid.9,10 Therefore, to achieve a balance
between potential efficacy and drug toxicity, we used 300 mg/day
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